Followers | 3349 |
Posts | 85921 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Thursday, September 26, 2019 8:19:06 AM
Press Release | 09/26/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.
The updated report provides an overview of recent events, new initiatives, and the company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at its partner site, www.GoldmanResearch.com.
Marble Arch Research notes that, “With a number of competitive advantages in the space, a deep product pipeline and IP portfolio, combined with a clever financial model, we believe that the Company can enjoy hockey-stick type sales growth in the next 2-3 years. Plus, its new technology licensing for CBD use could prove to be a sleeper and a very profitable engine for PetVivo. Our target is based upon a 5.5x sales P/S multiple, similar to its peer group, and affirmed by a Net Present Value (NPV) calculation. In our view, the current price reflects an attractive entry point.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.
The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Recent PETV News
- PetVivo Taps Top Sales Executive, Skylor Walker, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide • GlobeNewswire Inc. • 09/16/2024 12:00:00 PM
- PetVivo’s Spryng with OsteoCushion™ Technology Featured in Visionaries on Bloomberg TV • GlobeNewswire Inc. • 09/12/2024 12:00:00 PM
- PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian • GlobeNewswire Inc. • 09/09/2024 02:22:00 PM
- Scot Cave Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager • GlobeNewswire Inc. • 09/03/2024 02:27:00 PM
- PetVivo Teams with Orthobiologic Innovations for Clincial Research and Product Commercialization • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager • GlobeNewswire Inc. • 08/19/2024 02:10:00 PM
- PetVivo Reports Reports Fiscal Q1 2025 Results • GlobeNewswire Inc. • 08/14/2024 08:25:00 PM
- Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager • GlobeNewswire Inc. • 08/12/2024 05:52:00 PM
- PetVivo Sets Fiscal First Quarter 2025 Conference Call for Wednesday, August 14 at 5:00 p.m. ET • GlobeNewswire Inc. • 08/08/2024 02:25:00 PM
- PetVivo Reports Reports Fiscal 2024 Results • GlobeNewswire Inc. • 06/28/2024 08:41:38 PM
- PetVivo Sets Fiscal Fourth Quarter 2024 Conference Call for Friday, June 28 at 5:00 p.m. ET • GlobeNewswire Inc. • 06/25/2024 08:15:22 PM
- PetVivo Appoints Former NOVUS and Colgate-Palmolive Senior Sales & Marketing Executive, Bryan Monninger, as VP of Sales • GlobeNewswire Inc. • 06/06/2024 11:00:00 AM
- April Boyce Joins PetVivo Holdings, Inc. as the Vice President of Marketing • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA • GlobeNewswire Inc. • 04/08/2024 10:30:00 AM
- PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN NAPLES FLORIDA • GlobeNewswire Inc. • 04/03/2024 01:25:00 PM
- PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN CHARLESTON, SOUTH CAROLINA • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 02:19:16 PM
- Garry Lowenthal Joins PetVivo Holdings, Inc. as the Chief Financial Officer • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- New to The Street Announces its Five Corporate TV Interviews, Airing Episode 561 on the FOX Business Network Monday, March 11, 2024, at 10:30 PM PT • GlobeNewswire Inc. • 03/08/2024 02:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/07/2024 10:19:48 PM
- New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT • GlobeNewswire Inc. • 03/07/2024 02:37:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 08:54:02 PM
- PetVivo Holdings, Inc. Commences Trading on Upstream Under PETV • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- New to The Street Announces its Line-up, Four Corporate Interviews Airings on The FOX Business Network, Monday, March 4, 2024, at 10:30 PM PT • GlobeNewswire Inc. • 03/01/2024 02:30:00 PM
- Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM